Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats relapsing forms of multiple sclerosis. Sold as Tyruko. Every FDA application for this active ingredient. Boxed warningREMS safety program
As of Nov 22, 2026, FDA lists 1 application for Natalizumab-sztn (sold as Tyruko), first approved Aug 24, 2023, with 0 new uses approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Stopped early: “The ascend study did not achieve statistical significance on the primary or secondary endpoints.”
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
First approved in Japan 113 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Tysabri, new ingredientA drug with a new active ingredient indicated for the prevention of relapse and for delaying the accumulation of physical disability in multiple sclerosis. · Biogen Idec Japan Ltd. · Mar 24, 2014
Approvals in Canada (Health Canada)
First approved in Canada 203 months before the US. New drug submissions since 1994, matched by ingredient; see all Canadian approvals
FDA requires these when a drug's risks need more than a label: training, enrollment or extra checks before it is prescribed or dispensed
Program
Updated
Tyruko REMSRestricted: prescribers, pharmacies or patients must be certified or enrolled · Medication Guide for patients
Jul 23, 2026
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA